HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel tyrosine-modified low molecular weight polyethylenimine (P10Y) for efficient siRNA delivery in vitro and in vivo.

Abstract
The delivery of nucleic acids, particularly of small RNA molecules like siRNAs for the induction of RNA interference (RNAi), still represents a major hurdle with regard to their application in vivo. Possible therapeutic applications thus rely on the development of efficient non-viral gene delivery vectors. While low molecular weight polyethylenimines (PEIs) have been successfully explored, the introduction of chemical modifications offers an avenue towards the development of more efficient vectors. In this paper, we describe the synthesis of a novel tyrosine-modified low-molecular weight polyethylenimine (P10Y) for efficient siRNA complexation and delivery. The comparison with the respective parent PEI reveals that knockdown efficacies are considerably enhanced by the tyrosine modification, as determined in different reporter cell lines, without appreciable cytotoxicity. We furthermore identify optimal conditions for complex preparation as well as for storing or lyophilization of the complexes without loss of biological activity. Beyond reporter cell lines, P10Y/siRNA complexes mediate the efficient knockdown of endogenous target genes and, upon knockdown of the anti-apoptotic oncogene survivin, tumor cell inhibitory effects in different carcinoma cell lines. Pushing the system further towards its therapeutic in vivo application, we demonstrate in mice the delivery of intact siRNAs and distinct biodistribution profiles upon systemic (intravenous or intraperitoneal) injection. No adverse effects (hepatotoxicity, immunostimulation/alterations in immunophenotype, weight loss) are observed. More importantly, profound tumor-inhibitory effects in a melanoma xenograft mouse model are observed upon systemic application of P10Y/siRNA complexes for survivin knockdown, indicating the therapeutic efficacy of P10Y/siRNA complexes. Taken together, we (i) establish tyrosine-modified PEI (P10Y) as efficient platform for siRNA delivery in vitro and in vivo, (ii) identify optimal preparation and storage conditions as well as (iii) physicochemical and biological properties of P10Y complexes, and (iv) demonstrate their applicability as siRNA therapeutic in vivo (v) in the absence of adverse effects.
AuthorsAlexander Ewe, Susanne Przybylski, Jana Burkhardt, Andreas Janke, Dietmar Appelhans, Achim Aigner
JournalJournal of controlled release : official journal of the Controlled Release Society (J Control Release) Vol. 230 Pg. 13-25 (05 28 2016) ISSN: 1873-4995 [Electronic] Netherlands
PMID27061141 (Publication Type: Journal Article)
CopyrightCopyright © 2016 Elsevier B.V. All rights reserved.
Chemical References
  • Birc5 protein, mouse
  • Inhibitor of Apoptosis Proteins
  • RNA, Small Interfering
  • Repressor Proteins
  • Survivin
  • Tyrosine
  • Polyethyleneimine
Topics
  • Animals
  • Cell Line, Tumor
  • Gene Transfer Techniques
  • Humans
  • Inhibitor of Apoptosis Proteins (genetics)
  • Melanoma (drug therapy, genetics)
  • Mice, Nude
  • Molecular Weight
  • Polyethyleneimine (administration & dosage, chemistry)
  • RNA, Small Interfering (administration & dosage, chemistry)
  • Repressor Proteins (genetics)
  • Survivin
  • Tyrosine (administration & dosage, chemistry)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: